


Representative Life Science Deals

- Over \$8.0 Billion in Commitments to more than 430 Companies since 2003
- Total New Debt & Equity Commitments of ~\$728.7 Million YTD
- Total New Fundings of ~\$563.7 Million YTD
- Over 1,000 Co-investments with Different VC & PE Firms in the Last 14 Years
- Over 130 Companies completed IPO or M&A Events since Inception

**\$50,000,000
Debt Commitment**

Invested in 2018
NASDAQ: MESO



**\$75,000,000
Debt Commitment**
**\$2,000,000
Equity Commitment**

Invested in 2018
NASDAQ: TCDA



**\$30,000,000
Debt Commitment**

Invested in 2011, 2013, 2015,
2017
NASDAQ: ACRX



**\$35,000,000
Debt Commitment**

Invested in 2017
NASDAQ: ATRS



**\$20,000,000
Debt Commitment**

Invested in 2017
NASDAQ: BOLD



**\$55,000,000
Debt Commitment**

Invested in 2017
NASDAQ: AXON




**\$30,000,000
Debt Commitment**

Invested in 2016, 2017
NASDAQ: BLCM



**\$25,000,000
Debt Commitment**

Invested in 2017
NASDAQ: CCXI




**\$30,000,000
Debt Commitment**

Invested in 2017




**\$40,000,000
Debt Commitment**

Invested in 2017
NYSE: MYOV



**\$30,000,000
Debt Commitment**

Invested in 2017



**\$15,000,000
Debt Commitment**
**\$1,000,000
Equity Commitment**

Invested in 2014, 2015,
2016, 2017
NASDAQ: QTRX



\$35,000,000
Debt Commitment

Invested in 2018



\$40,000,000
Debt Commitment

Invested in 2018
NASDAQ: TRXC



\$30,000,000
Debt Commitment
\$20,000,000
Prior Debt Commitment

Invested in 2011, 2012, 2017
NASDAQ: CNCE



\$60,000,000
Debt Commitment
\$1,000,000
Equity Commitment

Invested in 2014, 2015, 2016, 2017
NASDAQ: PRTK



\$20,000,000
Debt Commitment

Invested in 2017



\$45,000,000
Debt Commitment

Invested in 2014, 2015, 2016
NASDAQ: ALIM



\$55,000,000
Debt Commitment
\$1,000,000
Equity Commitment

Invested in 2014, 2015
Acquired by Jazz Pharma in 2016



\$60,000,000
Debt Commitment

Invested in 2016
NASDAQ: SRNE



\$15,000,000
Debt Commitment

Invested in 2014, 2015
Acquired by Jazz Pharma in 2016



\$40,000,000
Debt Commitment
\$550,000
Equity Commitment

Invested in 2014, 2015
NASDAQ: DVAX



\$30,000,000
Debt Commitment
\$2,000,000
Prior Debt Commitment

Invested in 2014, 2015
NASDAQ: MLNT



\$25,000,000
Debt Commitment
\$55,000,000
Prior Debt Commitment

Invested in 2005, 2007, 2012, 2015
NASDAQ: MACK



\$8,500,000
Debt Commitment
\$2,500,000
Equity Commitment

Invested in 2008, 2010,
2012, 2015



\$20,000,000
Debt Commitment

Invested in 2013, 2014
NASDAQ: QURE



\$45,000,000
Debt Commitment

Invested in 2013
Acquired by Pfizer in 2016



\$22,000,000
Debt Commitment

Invested in 2011
NASDAQ: RVNC

Boston Office

R. Bryan Jadot

Sr. Managing Director
617.314.9981
bjadot@htgc.com

Kristen Kosofsky

Sr. Managing Director
617.851.5416
kkosofsky@htgc.com

Janice Bourque

Managing Director
617.314.9992
jbourque@htgc.com

Palo Alto Office

Nimesh Shah

Managing Director
650.433.5548
nshah@htgc.com

Himani Bhalla

Principal
650.433.5581
hbhalla@htgc.com

San Diego Office

Lake McGuire

Managing Director
517.304.0382
lmcguire@htgc.com

New York Office

Anup Arora

Managing Director
212.774.3612
aarora@htgc.com